Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis

BackgroundAngiotensin II receptor blockers (ARBs) are utilized for the management of hypertension and diabetes. Previous meta-analyses suggested that azilsartan medoxomil (AZL-M) improved blood pressure (BP) reduction, but there were no safety findings or suggestions for patients with hypertension o...

Full description

Bibliographic Details
Published in:	Frontiers in Cardiovascular Medicine
Main Authors:	Ling Zhu, Guo-Cui Wei, Qing Xiao, Qian-Lan Chen, Qian Zhao, Xiu-xia Li, Ling-ai Pan, Xuan Xiong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	azilsartan medoxomil hypertension diabetes meta-analysis angiotensin II receptor blockers (ARBs)
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2024.1383217/full

Similar Items

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
by: Attila Juhasz, et al.
Published: (2018-02-01)

Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone
by: M. D. Smirnova, et al.
Published: (2025-01-01)

MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL
by: V. V. Skibitsky, et al.
Published: (2017-12-01)

A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension
by: Hiromi Rakugi, et al.
Published: (2018-05-01)

Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension
by: Zh. D. Kobalava, et al.
Published: (2019-07-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.
by: Georgiopoulos Georgios, et al.
Published: (2016-08-01)

Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes
by: A. M. Kochergina, et al.
Published: (2023-11-01)

Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation
by: Girish Kumar, et al.
Published: (2022-10-01)

EFFICACY OF AZILSARTAN MEDOXOMIL ON THE DAILY PROFILE OF PERIPHERAL AND CENTRAL ARTERIAL PRESSURE AND ARTERIAL STIFFNESS IN HYPERTENSIVES WITH TYPE 2 DIABETES
by: E. A. Troitskaya, et al.
Published: (2017-02-01)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: R. P. Mason
Published: (2012-06-01)

Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesis in vivo via suppression of TNF-α expression in macrophages
by: Ziqiu Fan, et al.
Published: (2023-09-01)

Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction
by: Zh. D. Kobalava, et al.
Published: (2022-05-01)

Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review
by: Vadim D. Zakiev, et al.
Published: (2023-11-01)

Efficacy and safety of telmisartan monotherapy in the black hypertensive patient at a tertiary centre in Eastern Nigeria
by: C K Ijoma, et al.
Published: (2011-01-01)

Possible combined effect of perindopril and Azilsartan in an experimental model of dementia in rats
by: Yahya M. Alzahrani, et al.
Published: (2020-05-01)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review
by: Elisabeth M. Wang, et al.
Published: (2025-10-01)

Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis
by: Ji‐Guang Wang, et al.
Published: (2021-05-01)

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01)

Anti-hypertensive effect of a novel angiotensin II receptor neprilysin inhibitor (ARNi) -S086 in DSS rat model
by: Jingchao Sun, et al.
Published: (2024-02-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Case Report: Angiotensin converting enzyme inhibitors vs. angiotensin receptor blockers in the management of chronic hypertension: a case of lisinopril-induced rhinorrhea
by: Alice A. Amudzi, et al.
Published: (2024-11-01)

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System
by: Graham J. Moore, et al.
Published: (2022-07-01)

Effects of two different angiotensin receptor blockers on blood glucose level and HbA1c in type-2 diabetes mellitus patients with hypertension
by: Shafat Iqbal Bhati, et al.
Published: (2023-10-01)

Nephroprotective effect of vitamin E added to angiotensin receptor blocker in patients with diabetic nephropathy
by: Abdulrazzaq Alkaaby, et al.
Published: (2021-12-01)

Effects of ACEI/ARB or CCB use on atrial fibrillation in hypertensive patients following permanent pacemaker implantation
by: Zhijie Liu, et al.
Published: (2023-06-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study
by: JungMin Choi, et al.
Published: (2024-05-01)

Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: Lothar study
by: Vasiljević Zorana, et al.
Published: (2013-01-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis
by: Jing Liu, et al.
Published: (2024-12-01)

ACE inhibitor angioedema: characterization and treatment versus non-ACE angioedema in acute hospitalized patients
by: David S. Weisman, et al.
Published: (2020-01-01)

Influence of asilsartan medoxomile on arterial hypertension variability in patients with arterial hypertension and chronic obstructive pulmonary disease
by: N. Yu. Grigorieva, et al.
Published: (2021-06-01)

Drugs acting on the renin–angiotensin–aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies
by: Ruchika Sharma, et al.
Published: (2022-09-01)

Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: A pilot study
by: JungMin Choi, et al.
Published: (2021-09-01)

New targets and old therapies for arterial hypertension
by: S. R. Gilyarevsky, et al.
Published: (2019-04-01)

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)
by: Kazuomi Kario, et al.
Published: (2025-01-01)

Azilsartan, but not Candesartan Improves Left Ventricular Diastolic Function in Patients with Hypertension and Heart Failure
by: Mari Sakamoto, et al.
Published: (2015-12-01)

Comparison of NT-ProBNP Changes in Heart Failure Patients Following ACEI vs ARB Therapy
by: Intan Kusuma Dewi, et al.
Published: (2024-07-01)